Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Kudlow pointed to strong retail sales and low unemployment as signs that the U.S. economy remained strong.Marketsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The Supreme Court could strike down the constitutionality of the Consumer Financial Protection Bureau, an agency Elizabeth Warren has likened to her child and which Justice...2020 Electionsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Executives from seven pharmaceutical manufacturers will testify about drug pricing practices before the Senate Finance Committee "one way or another," Sen. Ron Wyden, D-Ore., said Tuesday.
Wyden and Sen. Chuck Grassley, R-Iowa, on Monday sent letters asking for representatives from the seven major drugmakers to testify at a Feb. 26 hearing. The seven companies are AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
Calling the pace of drug price increases "unsustainable," Grassley, who is the committee's chairman, said in a statement that he wants pharmaceutical executives to explain how they price these treatments, "whether the status quo is unacceptable" and what can be done to lower costs.
Wyden, the committee's ranking member, followed with a tweet Tuesday that stopped short of threatening to issue a subpoena, indicating that participation at the hearing isn't entirely voluntary. He said the companies "will come before the committee one way or another."
Grassley criticized pharmaceutical companies that declined his invitation to testify at last week's hearing about drug prices, adding that several of the companies asked to testify Feb. 26 declined his original request.
"The companies that declined said they would discuss their ideas in private, but not in public," Grassley said at the committee's Jan. 29 hearing. "That is not what I mean when I talk about transparency. So, we will extend the opportunity again in the future, but we will be more insistent the next time."
Wyden said at the time that the committee would use its "power to compel the drug company CEOs to show up" if they don't testify.
Two companies have agreed to send their CEOs to the hearing, a spokeswoman for Grassley said Tuesday. Merck CEO Ken Frazier will attend, a spokeswoman for the company told CNBC. Sanofi is determining whether current scheduling allows CEO Olivier Brandicourt to attend the hearing, a spokeswoman said. AstraZeneca told CNBC that "we are currently reviewing the request and will respond to the Committee in due course."
Lawmakers on both sides of the aisle have demanded something be done to lower drug prices. President Donald Trump has made lowering out-of-pocket costs for patients one of his administration's top priorities. He's expected to address the issue Tuesday night in his State of the Union address.